汇丰研究的报告指，科伦博泰(06990.HK) 的SKB264已启动12项全球第三期临床研究，反映海外合作伙伴对SKB264的信心强劲。
该行看好科伦博泰的SKB264商业化价值，认为其有利的竞争地位、强劲的临床证据，以及公司在医院及药房的庞大网络，均有助产品的销售增长，亦料SKB264可受惠于今年底国家医保药品目录对创新药物支持的讨论。
该行调整对科伦博泰的亏损预测，预期2024至2026年分别录得净亏损5亿、9亿及5亿元人民币。对其目标价由237元上调至260元，维持“买入”评级。(vc/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-06 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.